These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 15671919)

  • 1. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms.
    Scheen AJ
    Diabetes Metab; 2004 Dec; 30(6):498-505. PubMed ID: 15671919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials.
    Scheen AJ
    Diabetes Metab; 2004 Dec; 30(6):487-96. PubMed ID: 15671918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
    Scheen AJ
    Drugs; 2004; 64(22):2537-65. PubMed ID: 15516153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes.
    Jandeleit-Dahm KA; Tikellis C; Reid CM; Johnston CI; Cooper ME
    J Hypertens; 2005 Mar; 23(3):463-73. PubMed ID: 15716683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
    Yamagishi S; Takeuchi M
    Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of the renin-angiotensin system in the development of insulin resistance in skeletal muscle.
    Henriksen EJ; Prasannarong M
    Mol Cell Endocrinol; 2013 Sep; 378(1-2):15-22. PubMed ID: 22564510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin blockade prevents type 2 diabetes by formation of fat cells.
    Sharma AM; Janke J; Gorzelniak K; Engeli S; Luft FC
    Hypertension; 2002 Nov; 40(5):609-11. PubMed ID: 12411451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-diabetic effect of blockade of the renin-angiotensin system.
    Ando K; Fujita T
    Diabetes Obes Metab; 2006 Jul; 8(4):396-403. PubMed ID: 16776746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.
    Weber MA
    J Hypertens Suppl; 1997 Dec; 15(6):S31-6. PubMed ID: 9493125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control.
    Perkins JM; Davis SN
    Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):147-52. PubMed ID: 18316950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renin-angiotensin system blocking drugs.
    Robles NR; Cerezo I; Hernandez-Gallego R
    J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):14-33. PubMed ID: 24038019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Angiotensin II receptor blockers: current status and future prospects].
    Corvol P; Plouin PF
    Drugs; 2002; 62 Spec No 1():53-64. PubMed ID: 12036389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does interference with the renin-angiotensin system protect against diabetes? Evidence and mechanisms.
    van der Zijl NJ; Moors CC; Goossens GH; Blaak EE; Diamant M
    Diabetes Obes Metab; 2012 Jul; 14(7):586-95. PubMed ID: 22226145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection against death and renal failure by renin-angiotensin system blockers in patients with diabetes and kidney disease.
    Shen J; Huang YM; Song XN; Hong XZ; Wang M; Ling W; Zhang XX; Zhao HL
    J Renin Angiotensin Aldosterone Syst; 2016 Jul; 17(3):. PubMed ID: 27377659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of and risk factors for severe acute kidney injury in children with heart failure treated with renin-angiotensin system inhibitors.
    Terano C; Ishikura K; Miura M; Hamada R; Harada R; Sakai T; Hamasaki Y; Hataya H; Ando T; Honda M
    Eur J Pediatr; 2016 May; 175(5):631-7. PubMed ID: 26687571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of protective effects induced by blockade of the renin-angiotensin system: novel role of the pancreatic islet angiotensin-generating system in Type 2 diabetes.
    Leung PS
    Diabet Med; 2007 Feb; 24(2):110-6. PubMed ID: 17257271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renin-angiotensin-system blockade in the prevention of diabetes.
    Ostergren J
    Diabetes Res Clin Pract; 2007 May; 76 Suppl 1():S13-21. PubMed ID: 17320999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.